Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00041925 · ClinicalTrials.gov registry record · Phase 2
Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures
A Phase 2 study, sponsored by Anesiva.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,400
- Enrollment target
NCT00041925: Completed Phase 2 study, sponsored by Anesiva.
NCT00041925 is a Phase 2 study that has completed, run by Anesiva. The registered enrollment target is 1,400 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (953% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00041925, a Phase 2 study, has completed, sponsored by Anesiva.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat chronic critical limb ischemia; on the occurrence of clinically significant graft stenosis (more than or equal to 70%); and on the incidence of critical limb ischemia (e.g., gangrene, non-healing ischemic ulcers or ischemic rest pain).
Interventions
- DRUG CGT003 (E2F Duplex Decoy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2001-11 |
| Est. Completion | 2004-11 |
| Phase | Phase 2 |
What the finished NCT00041925 record still lists
NCT00041925 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (953% higher).
The record links to 0 conditions, and to 1 intervention - of which CGT003 (E2F Duplex Decoy) is the first listed.
NCT00041925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00041925 about?
NCT00041925 is a clinical study titled "Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures". The purpose of this study is to determine the efficacy of graft pretreatment with the E2F decoy, CGT003, as compared to placebo, on the occurrence of graft failure among patients who receive autogenous vein grafts to treat chronic critical limb ischemia; on the occurrence of clinically significant g...
What is the current status of trial NCT00041925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,400 participants. The study started on 2001-11. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00041925?
The interventions under investigation include: CGT003 (E2F Duplex Decoy) (DRUG).
Who is sponsoring clinical trial NCT00041925?
This trial is sponsored by Anesiva, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00041925's enrollment target sits among peer trials
1,400 12th of 2000 higher than 1,988 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia